These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26880862)

  • 21. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
    Ren X; Guan G; Liu G; Liu G
    Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EC approves irbesartan for the treatment of diabetic renal disease.
    Cardiovasc J S Afr; 2002; 13(4):216-7. PubMed ID: 12402931
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to "Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-
    Chen XW; Du XY; Wang YX; Wang JC; Liu WT; Chen WJ; Li HY; Peng FF; Xu ZZ; Niu HX; Long HB
    Mediators Inflamm; 2016; 2016():3151986. PubMed ID: 27829706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a GSK-3β inhibitor on the renal expression levels of RANK, RANKL and NF-κB in a rat model of diabetic nephropathy.
    Zhou YX; Shi LX; Yang H; Long YG; Meng LU; Lv LS; Zhang Y; Yao H; Li L; Yu YN
    Exp Ther Med; 2016 Jun; 11(6):2495-2502. PubMed ID: 27284338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
    Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
    Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
    Evans M; Bain SC; Hogan S; Bilous RW;
    Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
    Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
    Kaiser T; Florack C; Sawicki PT
    Diabetes Care; 2004 Jun; 27(6):1521; author reply 1521-2. PubMed ID: 15161820
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].
    Long HB; Zhong J; Wei LB; Zhou WD; Xu ZZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):505-8. PubMed ID: 17545045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic interaction of effective parts in Rehmanniae Radix and Cornus officinalis ameliorates renal injury in C57BL/KsJ-db/db diabetic mice: Involvement of suppression of AGEs/RAGE/SphK1 signaling pathway.
    Lv X; Dai G; Lv G; Chen Y; Wu Y; Shen H; Xu H
    J Ethnopharmacol; 2016 Jun; 185():110-9. PubMed ID: 26972502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Diabetic Nephropathy Activities of Polysaccharides Obtained from
    Yang C; Feng Q; Liao H; Yu X; Liu Y; Wang D
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640118
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition effect of enteropeptidase on RANKL-RANK signalling by cleavage of RANK.
    Zhao Y; Jin M; Ma J; Zhang S; Li W; Chen Y; Zhou Y; Tao H; Liu Y; Wang L; Han H; Niu G; Tao H; Liu C; Gao B
    FEBS Lett; 2013 Sep; 587(18):2958-64. PubMed ID: 23954298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes.
    Lee S; Kim W; Moon SO; Sung MJ; Kim DH; Kang KP; Jang KY; Lee SY; Park BH; Koh GY; Park SK
    Nephrol Dial Transplant; 2007 Feb; 22(2):396-408. PubMed ID: 17085463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-molecular-weight polyphenols protect kidney damage through suppressing NF-κB and modulating mitochondrial biogenesis in diabetic db/db mice.
    Liu HW; Wei CC; Chang SJ
    Food Funct; 2016 Apr; 7(4):1941-9. PubMed ID: 26960417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
    Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619
    [No Abstract]   [Full Text] [Related]  

  • 39. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy.
    Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Lu J; Zhang XL; Liu BC
    Acta Diabetol; 2015 Dec; 52(6):1045-56. PubMed ID: 25896009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.
    Nam DH; Lee MH; Kim JE; Song HK; Kang YS; Lee JE; Kim HW; Cha JJ; Hyun YY; Kim SH; Han SY; Han KH; Han JY; Cha DR
    Endocrinology; 2012 Mar; 153(3):1387-96. PubMed ID: 22234468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.